Jean Park, MD
Endocrinology, Diabetes & Metabolism · Baltimore, MDNPI 1861512592
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $11,495 of the $12,530 with a category attached, or 91.7%. Novo Nordisk AS accounts for 89.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $11,374 and has fallen 99.4% since, to $68 in 2025.
Across 33 payments — averaging $379.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$11K
- Eli Lilly$855
- Novo Nordisk$204
- Corcept Therapeutics$173
- Xeris Pharmaceuticals, Inc.$36
- Lilly USA, LLC$28
- plus $44 from 2 others
Across 1,707 payments — averaging $2168.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.6M
- Novo Nordisk AS$286K
- Sanofi US Services Inc.$174K
- Boehringer Ingelheim Pharma GmbH & Co.kg$128K
- Boehringer Ingelheim International GmbH$102K
- Janssen Research & Development, LLC$73K
- plus $345K from 8 others
What the payments were for
- Travel & lodging$11,49592%
- Food & beverage$1,0358%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 9 | $11,191 |
| Eli Lilly | 7 | $855 |
| Novo Nordisk | 4 | $204 |
| Corcept Therapeutics | 7 | $173 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $28 |
| Dexcom, Inc. | 1 | $24 |
| Medtronic | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$9,442
How this compares
$12,530 in reported general payments places this provider in the 85th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 322 | $585,791 |
| TrulicityDulaglutide | 234 | $381,025 |
| MounjaroTirzepatide | 75 | $107,568 |
| JardianceEmpagliflozin | 83 | $102,723 |
| RybelsusSemaglutide | 46 | $69,834 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 97 | $50,483 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $40,845 |
| Tresiba Flextouch U-100Insulin Degludec | 51 | $33,289 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $23,597 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 27 | $19,471 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 129 | $17,755 |
| JanuviaSitagliptin Phosphate | 21 | $17,399 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $15,378 |
| Novolog FlexpenInsulin Aspart | 45 | $13,990 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 108 | $10,451 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $204 | $655,625368 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $28 | $493,768322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Baltimore
- Philip LevinBaltimore$489K
- Adrian DobsBaltimore$149K
- Todd BrownBaltimore$143K
- Roberto SalvatoriBaltimore$53K
- Nowreen HaqBaltimore$40K
- Asif MohamedBaltimore$31K
- Sherita GoldenBaltimore$27K
- Mansur ShomaliBaltimore$11K
- Malek CheikhBaltimore$9K
- Paul SackBaltimore$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.